| Objective:To investigate the clinicopathological significance of Fas-associated death domain protein (FADD)
expression in breast cancer.Methods:The clinical data of breast cancer cases and relevant clinical data were collected. The expression of
FADD in breast benign lesion, breast cancer with or without lymph node metastasis and paired lymph node metastasis was detected by
immunohistochemical technique. The relationship between FADD expression and clinical pathological parameters of breast cancer
patients, such as age, tumor size, clinical stage, histological type and grade, estrogen and progesterone receptor level, and so on was
analyzed.Results:Immunohistochemistry results showed FADD positive expression rate of benign breast lesion group (85.1%, 40/47),
breast cancer group without lymph node metastasis (45.8%, 38/83), breast cancer group with lymph node metastasis(67.3%,72/107) and
paired lymph metastasis foci (45.8%, 49/107). There are significant difference between breast cancer without metastasis, breast cancer
with metastasis, lymph node foci and benign breast lesion group (respectively P < 0.001, = 0.022, < 0.001); in addition, FADD positive
expression rate of breast cancer grou with lymph node metastasis was higher than the other three groups (P = 0.003, < 0.001 and 0.022,
respectively). FADD expression is significantly associated with the patient's age at diagnosis (P = 0.049) and lymph node metastasis (P =
0.003), and there is significant correlation to tumor size, clinical staging, histological type, histological grade, estrogen and progesterone
receptors and c-erbB-2 expression situation and menstrual history (P > 0.05). Survival analysis showed that patients with FADD positive
expression had shorter survival time than FADD negative patients.Conclusion:FADD is associated with lymph node metastasis and
prognosis of breast cancer. |
